"CSL Behring continues to grow and expand its capacity to develop, manufacture, and supply a broad array of therapies around the world," said Paul Perreault, Executive Vice President of CSL Behring Worldwide Commercial Operations. "Canada is an extremely important market for us, and we look forward to delivering to Canadians the safe, effective, high-quality medicines for which our company has become known."
"One of Canadian Blood Services strategic directions for plasma protein products is to broaden its supplier base for commercial products and fractionation services," said Dr. Graham Sher, Chief Executive Officer of Canadian Blood Services. "This new partnership with CSL allows us to successfully achieve this strategic objective."
"With its long history of success in the biotherapies industry, CSL Behring Canada has shown it can perform as a trustworthy partner," said Dr. Francine Decary, President and CEO of Hema-Quebec. "We look forward to initiating what we expect to be a long and productive business relationship with CSL Behring in the supply of important medicines to patients in Quebec."
About Hemophilia A and von Willebrand Disease
Hemophilia is a bleeding disorder caused by a deficiency in one of the blood clotting factors (Factor VIII). Hemophilia A (often called classic hemophilia) accounts for about 80% of all hemophilia cases.
Hemophilia A is a hereditary disorder in which the clotting ability of the blood is impaired and excessive bleeding results. Small wounds and punctures are usually not a problem, but uncontrolled internal bleeding can result in pain and swelling as well as permanent damage, especially to joints and muscles.
The severity of symptoms can vary between individuals and the most
severe forms become apparent early on during a child's development.
Prolonged bleeding is the hallmark of hemophilia A and is typically first
noticed when an infant is circumcised. Additional ble
|SOURCE CSL Behring|
Copyright©2008 PR Newswire.
All rights reserved